Brighton Jones LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 45.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 80,361 shares of the medical equipment provider’s stock after purchasing an additional 25,252 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $3,508,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in BSX. Candriam S.C.A. raised its stake in Boston Scientific by 17.1% during the third quarter. Candriam S.C.A. now owns 430,284 shares of the medical equipment provider’s stock worth $18,851,000 after buying an additional 62,799 shares during the last quarter. Ethic Inc. grew its holdings in Boston Scientific by 11.1% during the 3rd quarter. Ethic Inc. now owns 232,231 shares of the medical equipment provider’s stock worth $10,137,000 after acquiring an additional 23,294 shares during the period. 180 Wealth Advisors LLC grew its holdings in Boston Scientific by 37.4% during the 3rd quarter. 180 Wealth Advisors LLC now owns 12,678 shares of the medical equipment provider’s stock worth $553,000 after acquiring an additional 3,453 shares during the period. StoneX Group Inc. raised its position in shares of Boston Scientific by 35.0% in the 3rd quarter. StoneX Group Inc. now owns 9,636 shares of the medical equipment provider’s stock worth $421,000 after acquiring an additional 2,499 shares in the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Boston Scientific by 15.0% in the 3rd quarter. Parallel Advisors LLC now owns 17,639 shares of the medical equipment provider’s stock worth $770,000 after acquiring an additional 2,301 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.
Boston Scientific Stock Performance
Shares of Boston Scientific stock opened at $42.82 on Monday. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $105.65. The firm has a market capitalization of $62.06 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 1.27 and a beta of 0.60. The business has a 50-day simple moving average of $44.32 and a 200 day simple moving average of $55.70. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. On average, research analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.
Analysts Set New Price Targets
BSX has been the topic of a number of recent analyst reports. Argus downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. UBS Group lowered their target price on Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, October 29th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Truist Financial cut their price target on Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Finally, Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $61.43.
Read Our Latest Research Report on Boston Scientific
Boston Scientific Company Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.
Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Boston Scientific serves healthcare providers and patients around the world.
Read More
- Five stocks we like better than Boston Scientific
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
